Valuation : CorMedix Inc.

Market Cap 671M 577M 542M 496M 925M 63.44B 933M 6.41B 2.5B 32.42B 2.52B 2.47B 104B P/E 2026 *
17.6x
P/E 2027 * 144x
Enterprise Value 671M 577M 542M 496M 925M 63.44B 933M 6.41B 2.5B 32.42B 2.52B 2.47B 104B EV / Sales 2026 *
1.99x
EV / Sales 2027 * 2.34x
Free-Float
92.42%
Yield 2026 *
-
Yield 2027 * -
1 day-0.64%
1 week+1.93%
Current month+2.54%
1 month+12.19%
3 months+2.92%
6 months+22.58%
Current year-27.17%
1 week 8.06
Extreme 8.06
8.74
1 month 7.1
Extreme 7.1
8.98
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
13.93
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 10/05/2022
Director of Finance/CFO 54 29/08/2025
Compliance Officer 66 12/12/2023
Director TitleAgeSince
Director/Board Member 67 06/08/2015
Chairman 81 03/08/2017
Director/Board Member 70 16/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
8/29/26 A Tax

Chief Financial Officer

-8,424 0.0107%
8/29/26 A Tax

Compliance Officer

-8,424 0.0107%
8/29/26 A Tax

Chief Operating Officer

-8,076 0.0103%
Change 5-day change 1-year change 3-year change Capi.($)
-1.63%+1.93%-38.18%+114.43% 671M
+0.46%+1.87%+80.97%+41.70% 374B
-1.54%-0.58%+27.64%-17.36% 70.56B
+1.00%+3.59%+48.04%+170.81% 12.45B
+1.67%-5.56%-7.74%-8.78% 7.89B
+0.12%-5.68%-13.86%+5.24% 4.98B
+0.12%-6.11%-28.60%+21.23% 4.47B
+2.70%+1.53%-34.44%-1.03% 3B
-0.14%-0.50%-2.14%+38.44% 2.56B
+0.13%-5.79%-28.46%-17.50% 2.01B
Average +0.37%-2.80%+0.32%+34.72% 48.27B
Weighted average by Cap. +0.04%-3.38%+67.11%+34.58%

Financials

2026 *2027 *
Net sales 337M 290M 272M 249M 465M 31.87B 468M 3.22B 1.25B 16.28B 1.27B 1.24B 52.45B 286M 246M 231M 212M 395M 27.08B 398M 2.74B 1.07B 13.84B 1.08B 1.05B 44.57B
Net income 45.66M 39.29M 36.87M 33.73M 62.96M 4.32B 63.45M 436M 170M 2.21B 171M 168M 7.1B 5.69M 4.89M 4.59M 4.2M 7.84M 537M 7.9M 54.31M 21.15M 275M 21.35M 20.89M 885M
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
03/09/26 $8.470 -1.63% 706,670
02/09/26 $8.610 +2.74% 1,102,064
01/09/26 $8.380 +1.45% 880,480
31/08/26 $8.260 -0.48% 980,535
28/08/26 $8.300 -0.12% 780,215
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.610USD
Average target price
15.40USD
Spread / Average Target
+78.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock